IBM and IBN Treating MRSA with Nanotechnology and Nanomedicine in February’s Edition of Healthcare Global

IBM and IBN Treating MRSA with Nanotechnology and Nanomedicine in February?s Edition of Healthcare Global

Carlsbad, CA, February 23, 2012 --(PR.com)-- In April 2011, researchers from IBM and the Institute of Bioengineering and Nanotechnology (IBN) announced that they had stumbled on “a nanomedicine breakthrough.” They discovered a new type of polymer which was able to detect and destroy bacteria that is resistant to antibiotics and infectious diseases such as MRSA. It is now hoped the discovery will have the potential to revolutionise treatments for MRSA and other superbugs which are becoming increasingly common in hospitals and healthcare environments across the world.

If commercially manufactured, these biodegradable nanostructures could be injected directly into the body or applied topically to the skin, treating skin infections through consumer products like deodorant, soap and hand sanitizer, as well as being used to help heal wounds, tuberculosis and lung infections.

To get a more up-to-date picture of how the discovery and development of this innovative new technique is progressing, Healthcare Global caught up with Dr James Hedrick, an IBM research scientist, in its March issue.

To read this article in full, visit: http://www.healthcareglobal.com/healthcare_technology/treating-mrsa-with-nanotechnology-and-nanomedicine

About Healthcare Global

Healthcare Global is a pioneering digital media site for Healthcare professionals and executives responsible for all aspects of managing this environment. Healthcare Global covers solutions that enable global healthcare executives to improve the way they manage their operations. Healthcare Global is the industry-dedicated arm of the WDM Group. Founded in 2007 by entrepreneur Glen White, WDM Group retains a diversified portfolio of websites, magazines, mobile apps, daily news feeds and weekly e-newsletters that leverage technology to innovatively deliver high-quality content, analytical data, and industry news.

Healthcare Global is headquartered in San Diego, California, with additional offices in Boston, Toronto, Mumbai and Norwich, England. For more information, contact 760-827-7800 or visit http://www.healthcareglobal.com.

###

Read this article:
IBM and IBN Treating MRSA with Nanotechnology and Nanomedicine in February’s Edition of Healthcare Global

Injectable gel could repair damaged cardiac tissue

SAN DIEGO — University of California, San Diego researchers have developed a new injectable hydrogel that could be an effective and safe treatment for tissue damage caused by heart attacks.

The study by Karen Christman and colleagues appears in today's (Feb. 21) issue of the Journal of the American College of Cardiology. Christman is a professor in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering and has co-founded a company, Ventrix, Inc., to bring the gel to clinical trials within the next year.

Therapies like the hydrogel would be a welcome development, Christman explained, since there are an estimated 785,000 new heart attack cases in the United States each year, with no established treatment for repairing the resulting damage to cardiac tissue.

The hydrogel is made from cardiac connective tissue that is stripped of heart muscle cells through a cleansing process, freeze-dried and milled into powder form, and then liquefied into a fluid that can be easily injected into the heart. Once it hits body temperature, the liquid turns into a semi-solid, porous gel that encourages cells to repopulate areas of damaged cardiac tissue and to preserve heart function, according to Christman. The hydrogel forms a scaffold to repair the tissue and possibly provides biochemical signals that prevent further deterioration in the surrounding tissues.

“It helps to promote a positive remodeling-type response, not a pro-inflammatory one in the damaged heart,” Christman said.

What’s more, the researchers’ experiments show that the gel also can be injected through a catheter, a method that is minimally invasive and does not require surgery or general anesthesia.

New, unpublished work by her research team suggests that the gel can improve heart function in pigs with cardiac damage, which brings this potential therapy one step closer to humans, said Christman.

There are few injectable cardiac therapies in development designed to be used in large animals such as pigs, which have a heart that is similar in size and anatomy to the human heart, Christman explained. “Most of the materials that people have looked at have been tested in rats or mice, and they are injectable via a needle and syringe. However, almost all of them are not compatible with catheter delivery and would gel too quickly, clogging the catheter during the procedure."

In experiments with rats, the gel was not rejected by the body and did not trigger arrhythmic heart beating, providing some assurance that the gel will be similarly safe for humans, the researchers note.

Christman has an equity interest in Ventrix, Inc., a company that may potentially benefit from the research results, and also serves on the company’s Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

The study’s co-authors include Jennifer Singelyn, Priya Sundaramurthy, Todd Johnson, Pamela Schup-Magoffin, Diane Hu, Denver Faulk, Jean Wang and Kristine M. Mayle in the Department of Bioengineering; Kendra Bartels, Anthony N. DeMaria, and Nabil Dib of the UC San Diego  School of Medicine; and Michael Salvatore and Adam M. Kinsey of Ventrix, Inc. The research was funded in part by the National Institutes of Health Director’s New Innovator Award Program (part of the NIH Roadmap for Medical Research), the Wallace H. Coulter Foundation, and the National Science Foundation.

Read more:
Injectable gel could repair damaged cardiac tissue

DNA2.0 Partners with Cosmo Bio to Deliver Bioengineering Solutions to Japanese Researchers

DNA2.0 today announced the selection of Cosmo Bio Co., Ltd. as the non-exclusive distributor in Japan for DNA2.0’s complete line of bioengineering solutions.

Menlo Park, Calif. (PRWEB) February 21, 2012

DNA2.0 today announced the selection of Cosmo Bio Co., Ltd. as the non-exclusive distributor in Japan for DNA2.0’s complete line of bioengineering solutions, including gene synthesis powered by GeneGPS for maximal protein expression as well as the company’s protein engineering solutions—ProteinGPS for rational protein design and Protein Variant Libraries for directed evolution. Cosmo Bio is a well-established distributor of reagents, instruments and services for researchers in academia, government and the biopharma industry, with over 20 years experience and 200 sales outlets throughout Japan.

“We are pleased to bring DNA2.0’s innovative approaches to gene design and optimization, gene synthesis and protein engineering to Japan through Cosmo Bio,” said Claes Gustafsson, COO and cofounder of DNA2.0. “The life science research and drug discovery community in Japan represents a significant market opportunity for DNA2.0, and Cosmo Bio’s customer-centered reputation makes it the natural choice to provide in-country services and support tailored to Japanese research needs.”

International customers can access DNA2.0’s Ph.D. experts in the fields of protein expression, gene synthesis and bioinformatics directly, however this distribution agreement with Cosmo Bio offers Japanese customers added flexibility and time savings, along with service and support in Japanese. All DNA2.0 sequences, tools and solutions are made at the company’s state-of-the-art facility in Menlo Park, ensuring the greatest security for intellectual property.

About DNA2.0

DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.

About Cosmo Bio

Cosmo Bio delivers the most up-to-date technical information and provides products made by world-class manufacturers to laboratories at educational, research and testing institutes working in the field of life science throughout Japan and around the world. The company takes pride in a service that fulfills the needs of our customers with extensive product lines and related information. Making full use of an international network, coupled with highly reliable information, Cosmo Bio supports the life science community with the high levels of commitment and responsibility required to maintain the trust of valued customers. For more information, please visit http://www.cosmobio.co.jp/index_e.asp.

###

Eric Schubert
DNA 2.0
415-939-4366
Email Information

See more here:
DNA2.0 Partners with Cosmo Bio to Deliver Bioengineering Solutions to Japanese Researchers

Three UI professors win Sloan fellowships

URBANA — Three University of Illinois professors have been awarded prestigious Sloan Research Fellowships in recognition of their potentially ground-breaking research in physics, math and bioengineering.

Neal Dalal, Vera Mikyoung Hur and Sheng Zhong are among 126 early-career scientists and researchers from 51 colleges and universities chosen for a two-year fellowship from the Alfred P. Sloan Foundation. The program awards $50,000 for the scientists to use toward their research.

"Today's Sloan Research Fellows are tomorrow's Nobel Prize winners," Paul Joskow, president of the foundation, said in a release. "These outstanding men and women are responsible for some of the most exciting science being done today."

Dalal, an astronomy professor, investigates the fundamental physics of cosmology, including the structure of the universe, the formation of galaxies and mysterious components in the universe such as dark matter and dark energy, according to a UI news release.

He developed a simple model describing the physical properties of dark matter halos, which surround all observed stars and galaxies. His group devised an entirely new probe of inflation, or expansion, in the early universe based on the clustering of galaxies and their host halos.

Dalal received his doctorate in astronomy from the University of California at San Diego in 2002. He received a Hubble Fellowship from the Space Telescope Science Institute and was a senior research associate at the Canadian Institute for Theoretical Astrophysics before joining the UI faculty in 2011.

Hur is a mathematician who models water waves, from ripples to tsunamis, according to the Sloan Foundation. She studies nonlinear partial differential equations that arise in physical contexts, with particular interest in wave motions at the surface of water and related interfacial fluids flows. She explores geometric and physical properties of permanent and progressive waves in the ocean. Recently, she has been also working on problems at the interface of partial differential equations and probability.

Hur earned her doctorate in mathematics at Brown University in 2006. She was an instructor at the Massachusetts Institute of Technology before joining the UI faculty in 2009.

Zhong, a professor of bioengineering, studies causal relationships among gene regulation, cell differentiation and cancer. His lab pioneered systems biology modeling, stem-cell engineering and single-cell technologies.

Zhong made important discoveries on the genetic differences of early embryonic development among humans, mice and cows. His work helped open the field of "comparative epigenomics" — using cross-species comparison to annotate genomes.

Zhong earned his doctorate in biostatistics at Harvard University in 2005. He is also a professor of biophysics and neuroscience and affiliated with the departments of computer science, statistics, and cell and developmental biology; the Beckman Institute for Advanced Science and Technology; the Institute for Genomic Biology; and the National Center for Supercomputer Applications.

Sloan research fellowships have been awarded since 1955. Candidates are nominated by their peers and selected by an independent panel of senior scholars.

For a complete list of winners, visit: http://www.sloan.org/fellowships/page/21

Read more from the original source:
Three UI professors win Sloan fellowships

IBM and IBN Treating MRSA With Nanotechnology and Nanomedicine in February's Edition of Healthcare Global

SOURCE: Healthcare Global

NORWICH, UNITED KINGDOM--(Marketwire - Feb 21, 2012) - In April 2011 researchers from IBM and the Institute of Bioengineering and Nanotechnology (IBN) announced that they had stumbled on "a nanomedicine breakthrough." They discovered a new type of polymer which was able to detect and destroy bacteria that is resistant to antibiotics and infectious diseases such as MRSA. It is now hoped the discovery will have the potential to revolutionise treatments for MRSA and other superbugs which are becoming increasingly common in hospitals and healthcare environments across the world.

If commercially manufactured, these biodegradable nanostructures could be injected directly into the body or applied topically to the skin, treating skin infections through consumer products like deodorant, soap and hand sanitizer, as well as being used to help heal wounds, tuberculosis and lung infections.

To get a more up-to-date picture of how the discovery and development of this innovative new technique is progressing, Healthcare Global caught up with Dr James Hedrick, an IBM research scientist, in its March issue.

To read this article in full, visit http://www.healthcareglobal.com or read the February issue Healthcare Global digital magazine.

About Healthcare Global

Healthcare Global is a pioneering digital media site for Healthcare professionals and executives responsible for all aspects of managing this environment. Healthcare Global covers solutions that enable global healthcare executives to improve the way they manage their operations. Healthcare Global is the industry-dedicated arm of the WDM Group. Founded in 2007 by entrepreneur Glen White, WDM Group retains a diversified portfolio of websites, magazines, mobile apps, daily news feeds and weekly e-newsletters that leverage technology to innovatively deliver high-quality content, analytical data, and industry news.

Healthcare Global is headquartered in San Diego, California, with additional offices in Boston, Toronto, Mumbai and Norwich, England. For more information, contact 760-827-7800 or visit http://www.healthcareglobal.com.

Read the original:
IBM and IBN Treating MRSA With Nanotechnology and Nanomedicine in February's Edition of Healthcare Global

For UC Berkeley’s New Helios Energy Research Facility: Firespray’s Ductwork Solves Lab Construction Challenge

BERKELEY, Calif.--(BUSINESS WIRE)--

Firespray International has provided an innovative lab exhaust ductwork system for the University of California, Berkeley’s (UC Berkeley) Helios Energy Research Facility (rendering), solving a complex construction challenge at the 113,000 square-foot building under construction in downtown Berkeley.

The structure will house the Energy Biosciences Institute (EBI) and the University’s Bioengineering Program. Dedicated to finding solutions to global climate change, the EBI is a collaboration of academic experts and energy industry leaders researching new carbon-neutral biofuels and examining biofuels’ potential environmental, social and economic impacts. UC Berkeley, the University of Illinois and Lawrence Berkeley National Laboratory partnered with the funding agency, energy company BP, to assemble the Institute’s researchers and staff.

The five-story facility is being built to achieve Leadership in Energy and Environmental Design (LEED) Silver certification. In the design phase, when architectural firm SmithGroupJJR and the Design Engineer, Gaynor, Inc. sought a solution for extremely constrained above-ceiling space, San Jose-based Critchfield Mechanical, Inc. (CMI) proposed Firespray’s Flamebar BW11 lab exhaust ductwork as a space-saving, “single-fix” approach.

“Our project incorporated Flamebar in lieu of using horizontal shaft-wall construction,” said Gabe Pattee, Project Engineer with general contractor Rudolph and Sletten. “As top-tier lab space, Helios was a project with robust, space consuming MEP systems. During our 3D modeling effort, we found Flamebar to be a fantastic value engineering idea to maintain architectural design, save time on schedule and save money,” Pattee added. “The combination of schedule savings and elimination of the horizontal shafts proved to be an economically advantageous benefit to the project.”

Fully compliant with the International Mechanical Code (IMC) and Uniform Mechanical Code (UMC), Firespray’s lab exhaust system is approved by the University of California (Berkeley, San Francisco and Irvine) for use on its campuses. “Eliminating the need for a drywall shaft, Firespray’s system reduced the assembly’s footprint by more than a foot horizontally and vertically,” said Joe Vincenti, vice president, Firespray USA.

“In the lab building’s tightly packed mechanical space, Flamebar BW11 was the only viable solution to make a substantial amount of construction work far easier,” noted architect Johnny Wong of SmithGroupJJR. “As we consider the system for future projects, a key is that it’s listed and accepted under stringent requirements of UL, the University Inspector of Record and the California State Fire Marshal.”

The system features factory-sprayed, stainless steel ductwork fabricated to an enhanced SMACNA standard. Firespray licensee Pacific Firespray applied coating for nearly 5,000 square feet of fire-rated ductwork, which CMI fabricated and installed.

Firespray International is recognized worldwide in design and manufacture of specialized fire ducting systems in sectors including fire-rated ductwork (lab exhaust, smoke exhaust, pressurization, car park exhaust, risers in multi story buildings) and commercial kitchen extract ductwork. For information and system documentation contact: Joe Vincenti, Firespray International, 972-365-5302 or info@firesprayusa.com.

More:
For UC Berkeley’s New Helios Energy Research Facility: Firespray’s Ductwork Solves Lab Construction Challenge

World’s First Lab-Engineered Burger Just Months Away

A team of privately funded Dutch researchers have reached a benchmark in the science of bioengineering. Using only stem cells, they’ve managed to grow a strip of muscle tissue in a Petri dish with the aim of eventually developing techniques for the mass production of eco-friendly lab-engineered meat.

By October of this year, Dr. Mark post of Maastricht University hopes to have world-renowned chef Heston Blumenthal of England’s famous Fat Duck restaurant cook-up the world’s first lab-engineered hamburger for an as yet unannounced celebrity taste-tester.

At a total production cost of roughly $320,000, it promises to be the most expensive hamburger ever created.

The research has been sponsored by a single anonymous donor who hopes that the project will pave the way for a more environmentally sustainable approach to meat production, one that cuts down on the enormous resources required in raising cattle while simultaneously the greenhouse gas emissions that result from it.

A fact seldom mentioned in the discussion on global warming is the significant role played by the world’s livestock population in releasing methane gas into the atmosphere—a greenhouse gas that’s some 20 times more harmful to than the carbon dioxide released from burning fossil fuels.

And with the inhabitants of up-and-coming countries like China quickly developing a taste for the luxuries enjoyed by their western counterparts, many fear that meat will become an increasingly expensive item available to an ever smaller percentage of the population.

“Meat demand is going to double in the next 40 years and right now we are using 70% of all our agricultural capacity to grow meat through livestock,” explained Dr. Post in a recent news conference.

“You can easily calculate that we need alternatives. If you don’t do anything meat will become a luxury food and be very, very expensive.”

Post explained that his team focused their research specifically on growing artificial beef because cattle require more resources per pound of meat than almost any other commercially raised livestock.

“Cows and pigs have an efficiency rate of about 15%, which is pretty inefficient. Chickens are more efficient and fish even more,” he explained to Ian Sample of The Guardian newspaper.

“If we can raise the efficiency from 15% to 50% it would be a tremendous leap forward.”

At the moment, the lab production of beef is still a long and grueling process. Using their current technique, Post’s team individually grew small sheets of muscle tissue, each 1.2 inches long, 0.6 inches wide and 0.02 inches thick. To make just a single burger, the team will have to combine some 3,000 of these sheets together with a few hundred sheets of similarly grown fatty tissue.

Moreover, Post concedes that they’re not yet sure how the meat will taste.

Still, like early computers that required entire rooms full of machines just to make simple computations, this method of meat production is still in its earliest phase. With the speed at which technology develops today, Post believes it entirely plausible that a few more years of research could make their current techniques thousands of times more efficient.

“I’d estimate that we could see mass production in another 10 to 20 years,” he told Sample.

At the annual meeting of the American Association for the Advancement of Science in Vancouver last week, Post noted that the significance of their burger would be largely symbolic, a “proof of concept.” What it shows, he told an audience of his fellow scientists, is that “with in-vitro methods, out of stem cells we can make a product that looks like and feels and hopefully tastes like meat.”

In addition to the environmentally friendly features of Petri-dish meat (which will, by the way, require some brilliant marketing to sell), it also has the potential to provide significant health advantages. Because the production of the meat is closely controlled at each stage, the scientists speculate that it would be relatively easy to develop meat with additional, targeted health benefits, such as lower levels of saturated fats and higher levels of heart-healthy polyunsaturated fatty acids.

Moreover, the potential to experiment with previously unfamiliar meats is essentially limitless, giving even the most adventurous palettes something to fantasize about.

“We could make panda meat, I’m sure we could,” said Post.

On the Net:

Read the rest here:
World’s First Lab-Engineered Burger Just Months Away

Injectable gel could repair tissue damaged by heart attack

ScienceDaily (Feb. 21, 2012) — University of California, San Diego researchers have developed a new injectable hydrogel that could be an effective and safe treatment for tissue damage caused by heart attacks.

The study by Karen Christman and colleagues appears in the Feb. 21 issue of the Journal of the American College of Cardiology. Christman is a professor in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering and has co-founded a company, Ventrix, Inc., to bring the gel to clinical trials within the next year.

Therapies like the hydrogel would be a welcome development, Christman explained, since there are an estimated 785,000 new heart attack cases in the United States each year, with no established treatment for repairing the resulting damage to cardiac tissue.

The hydrogel is made from cardiac connective tissue that is stripped of heart muscle cells through a cleansing process, freeze-dried and milled into powder form, and then liquefied into a fluid that can be easily injected into the heart. Once it hits body temperature, the liquid turns into a semi-solid, porous gel that encourages cells to repopulate areas of damaged cardiac tissue and to preserve heart function, according to Christman. The hydrogel forms a scaffold to repair the tissue and possibly provides biochemical signals that prevent further deterioration in the surrounding tissues.

"It helps to promote a positive remodeling-type response, not a pro-inflammatory one in the damaged heart," Christman said.

What's more, the researchers' experiments show that the gel also can be injected through a catheter, a method that is minimally invasive and does not require surgery or general anesthesia.

New, unpublished work by her research team suggests that the gel can improve heart function in pigs with cardiac damage, which brings this potential therapy one step closer to humans, said Christman.

There are few injectable cardiac therapies in development designed to be used in large animals such as pigs, which have a heart that is similar in size and anatomy to the human heart, Christman explained. "Most of the materials that people have looked at have been tested in rats or mice, and they are injectable via a needle and syringe. However, almost all of them are not compatible with catheter delivery and would gel too quickly, clogging the catheter during the procedure.

In experiments with rats, the gel was not rejected by the body and did not trigger arrhythmic heart beating, providing some assurance that the gel will be similarly safe for humans, the researchers note.

Christman has an equity interest in Ventrix, Inc., a company that may potentially benefit from the research results, and also serves on the company's Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

The study's co-authors include Jennifer Singelyn, Priya Sundaramurthy, Todd Johnson, Pamela Schup-Magoffin, Diane Hu, Denver Faulk, Jean Wang, and Kristine M. Mayle in the Department of Bioengineering; Kendra Bartels, Anthony N. DeMaria, and Nabil Dib of the UC San Diego School of Medicine; and Michael Salvatore and Adam M. Kinsey of Ventrix, Inc. The research was funded in part by the National Institutes of Health Director's New Innovator Award Program (part of the NIH Roadmap for Medical Research), the Wallace H. Coulter Foundation, and the National Science Foundation.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of California, San Diego, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Jennifer M. Singelyn, Priya Sundaramurthy, Todd D. Johnson, Pamela J. Schup-Magoffin, Diane P. Hu, Denver M. Faulk, Jean Wang, Kristine M. Mayle, Kendra Bartels, Michael Salvatore, Adam M. Kinsey, Anthony N. DeMaria, Nabil Dib, and Karen L. Christman. Catheter-Deliverable Hydrogel Derived From Decellularized Ventricular Extracellular Matrix Increases Endogenous Cardiomyocytes and Preserves Cardiac Function Post-Myocardial Infarction. J. Am. Coll. Cardiol., February 21, 2012; 59: 751 - 763 DOI: 1016/j.jacc.2011.10.888

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Read more from the original source:
Injectable gel could repair tissue damaged by heart attack

American Oriental Bioengineering Inc. Announces Plans for Reverse Stock Split of its Common Stock

NEWARK, N.J., Feb. 21, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB - News) (the "Company") today announced that on January 31, 2012, its board of directors adopted resolutions approving a reverse stock split (the "Reverse Split") of the outstanding shares of the Company's common stock ("Common Stock") at a ratio of one (1) share for every two (2) shares outstanding, so that every two (2) outstanding shares of Common Stock before the Reverse Split shall represent one (1) share of Common Stock after the Reverse Split.

Pursuant to the Company's Amended Articles of Incorporation filed with the Nevada Secretary of State, the maximum number of shares of Common Stock that the Company is authorized to issue will also be reduced from 150,000,000 to 75,000,000.  The Reverse Split will be effected without obtaining shareholder approval pursuant to Nevada law.  The effective date of the Reverse Split with the Nevada Secretary of State is set for Friday, February 24, 2012.  Accordingly, the New York Stock Exchange has set the effective date of the Reverse Split for Monday, February 27, 2012. The Reverse Split is part of the Company's strategy to maintain the listing of its shares on the New York Stock Exchange.

Currently, the Company has approximately 78,503,381 shares of Common Stock outstanding. After the Reverse Split, the Company would have approximately 39,251,867 shares outstanding.  Each stockholder's percentage ownership interest in the Company and proportional voting power will remain unchanged after the Reverse Split except for minor changes and adjustments resulting from rounding of fractional interests.  The rights and privileges of the holders of Common Stock shall be substantially unaffected by the Reverse Split.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

Hong Zhu
646-367-1765

Read the original:
American Oriental Bioengineering Inc. Announces Plans for Reverse Stock Split of its Common Stock

Discovery that migrating cells 'turn right' has implications for engineering tissues, organs

ScienceDaily (Feb. 17, 2012) — What if we could engineer a liver or kidney from a patient's own stem cells? How about helping regenerate tissue damaged by diseases such as osteoporosis and arthritis? A new UCLA study bring scientists a little closer to these possibilities by providing a better understanding how tissue is formed and organized in the body.

A UCLA research team discovered that migrating cells prefer to turn right when encountering changes in their environment. The researchers were then able to translate what was happening in the cells to recreate this left-right asymmetry on a tissue level. Such asymmetry is important in creating differences between the right and left sides of structures like the brain and the hand.

The research, a collaboration between the David Geffen School of Medicine at UCLA and the Center for Cell Control at UCLA's Henry Samueli School of Engineering and Applied Science, appears in the Feb. 17 issue of the journal Circulation Research.

"Our findings suggest a mechanism and design principle for the engineering of tissue," said senior author Dr. Linda L. Demer, a professor of medicine, physiology and bioengineering and executive vice chair of the department of medicine at the Geffen School of Medicine. "Tissue and organs are not simply collections of cells but require careful architecture and design to function normally. Our findings help explain how cells can distinguish and develop highly specific left-right asymmetry, which is an important foundation in tissue and organ creation."

Using microtechnology, the team engineered a culture surface in the lab with alternating strips of protein substrates that were cell-adhesive or cell-repellent, analogous to a floor with narrow horizontal stripes of alternating carpet and tile. Cells may encounter such surface changes when they travel through the body. ? The researchers observed that as the migrating cells crossed the interface between "carpet" and "tile" sections, they exhibited a significant tendency to turn right by 20 degrees, and, like a marching band, lined up in long, parallel rows, producing diagonal stripes over the entire surface.

"We had been noticing how these vascular cells would spontaneously form structures in cultures and wanted to study the process," said first author Ting-Hsuan Chen, a graduate student researcher in the department of mechanical and aerospace engineering at UCLA Engineering. "We had no idea our substrates would trigger the left-right asymmetry that we observed in the cells. It was completely unexpected.

"We found that cells demonstrated the ability to distinguish right from left and to self-organize in response to mechanical changes in the surfaces that they encounter. This provides insight into how to communicate with cells in their language and how to begin to instruct them to produce tissue-like architecture."

According to the researchers, the cells can sense the substrates beneath them, and this influences the direction of their migration and what shapes they form in the body. Of most interest, the researchers said, was the fact that the cells responded to the horizontal stripes by reorganizing themselves into diagonal stripes.

The team hopes to harness this phenomenon to use substrate interfaces to communicate with cells and instruct them to produce desired tissue structures for replacement. By adjusting the substrates, the researchers say, they have the potential to guide what structures the cells and tissue form.

The next stage of the research will be to control and guide cells to self-organize into two-dimensional and, eventually, three-dimensional patterns chosen by the researchers.

According to the research team, this is one of the first studies to demonstrate that encountering a change in substrate can trigger a cell's preference for turning left or right. It is also one of the first studies showing that cells can integrate left-right asymmetry into a patterned structure of parallel diagonal stripes resembling tissue architecture.

"Applications for this research may help in future engineering of organs from a patient's own stem cells," Demer said. "This would be especially important given the limited supply of donor organs for transplant and problems with immune rejection."

The study was funded by the National Science Foundation and National Institutes of Health.

Additional authors included Jeffrey J. Hsu, Alan Garfinkel and Yin Tintut from the UCLA Department of Medicine; Yi Huang and Chih-Ming Ho from the UCLA Department of Mechanical and Aerospace Engineering; Xin Zhao, Chunyan Guo and Zongwei Li from the Institute of Robotics and Automatic Information System at China's Nankai University; and Margaret Wong from the UCLA Department of Bioengineering.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of California, Los Angeles (UCLA), Health Sciences, via Newswise. The original article was written by Rachel Champeau.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

T.-H. Chen, J. J. Hsu, X. Zhao, C. Guo, M. N. Wong, Y. Huang, Z. Li, A. Garfinkel, C.-M. Ho, Y. Tintut, L. L. Demer. Left-Right Symmetry Breaking in Tissue Morphogenesis via Cytoskeletal Mechanics. Circulation Research, 2012; 110 (4): 551 DOI: 10.1161/CIRCRESAHA.111.255927

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Excerpt from:
Discovery that migrating cells 'turn right' has implications for engineering tissues, organs

After scrapping bigger plans, HP says webOS still has an open-source future

The future of webOS -- the innovative mobile software that three successive CEOs at Hewlett-Packard (HPQ) have struggled to make into a profitable product -- may lie somewhere in the windowless rooms of a Stanford Medical School radiology lab.

That's where researcher Andrew B. Holbrook is working on ways to operate a cutting-edge, million dollar medical scanner with the help of a discontinued model Palm smartphone that he bought online for $50.

HP had bigger things in mind for webOS when it paid $1.4 billion to buy Palm two years ago: Executives talked about putting Palm's critically praised software on millions of phones, tablets and even PCs. But after a predecessor abruptly abandoned those plans, CEO Meg Whitman decided in December that HP would release the code under an open-source license, which means other companies and individuals like Holbrook are free to come up with their own uses.

And while many experts say it's unlikely the software will ever supplant more widely used mobile operating systems from Apple (AAPL) or Google (GOOG), analysts say webOS could find a new life if developers use it to create applications for specialized automotive, industrial or medical equipment, such as Holbrook's MRI scanner.

Stanford's Holbrook, who has a Ph.D. in bioengineering and a tinkerer's enthusiasm for writing code, has been working with other researchers on using the MRI in conjunction with new treatment techniques for removing tumors or unwanted cells without invasive surgery. But as a sidelight, he's used webOS software to create new applications for tracking and adjusting some of the MRI's functions.

Holbrook uses those apps on a modified phone, as well as an HP TouchPad tablet, from which he's removed most of the metal components so he can take them into the room where patients are treated with the massive magnetic scanner.

That can save time, he notes, and perhaps let doctors and technicians interact more closely with patients. Most MRIs are typically operated with more bulky computer equipment that sits outside the heavily shielded scanner room, both to protect the computers from the powerful magnet and prevent them from causing radio frequency interference with the MRI image.

"These are incredibly useful tools," Holbrook said of the webOS gadgets. Holbrook added that he doesn't really want to go into the software business himself, but he's hoping that some health care company or medical device-maker will eventually pick up on his work.

Whether that creates any kind of financial return for HP remains to be seen.

"It's a head-scratcher," said Al Hilwa, a software analyst for the IDC research firm. "Clearly HP has decided they're not going to be able to make money on webOS right away. But it doesn't hurt to have a small ecosystem of developers who are still working on it out there."

HP acquired Palm in a 2010 deal negotiated by then-CEO Mark Hurd, who was ousted in an unrelated scandal before the company could launch new Palm products. His successor, Leo Apotheker, touted the first webOS tablet as a rival to Apple's iPad. But when initial sales proved weak, Apotheker abruptly halted production on new webOS devices last summer.

Experts debate the pros and cons of webOS: While critics said it could be slow at times, fans said it had innovative features, including an elegant approach to operating several applications at the same time.

Many believe HP's biggest problem was taking too long to bring its webOS products to market, after Apple locked up the tablet business and Google's Android had already become the leading alternative to Apple's software for smartphones and other gadgets.

Top HP executives, however, insist they're still enthusiastic for webOS. While ruling out new smartphones, Whitman told this newspaper in December that HP may one day produce webOS tablets again. She recently told the industry news outlet CRN that the software has "huge advantages" over both IS and Android, and that she still believes HP can build a business around it.

HP says it isn't ready to disclose plans for a webOS business. But Sam Greenblatt, a veteran HP manager now helping lead the webOS group, hinted in an interview that he expects other companies will find ways to use the software.

"I'm not going to tell you who's going to make hardware or who's not going to make hardware, but I don't believe webOS is going to be an orphan for long," he said.

Meanwhile, the company has announced a timetable for releasing elements of webOS over the coming months, until it's fully available under an Apache open-source license in September. Experts say that will give the company time to make sure none of the elements are subject to patent claims or other licensing issues.

HP also is adding some elements in hopes of making webOS more appealing to independent developers. These include an open-source development tool called Enyo, which programmers can use to create applications that will run on webOS and other mobile operating systems, including IS and Android, as well as on PC browsers such as Explorer and Firefox.

The additions acknowledge what most consider a rule of mobile software: Consumers won't use an operating system unless it comes with lots of applications that serve up information and services, but developers won't build new applications unless they can reach a wide audience of users.

By extending the reach of webOS developers to other operating systems, Greenblatt said, "more people are going to be writing more apps."

Analysts praised the new features, but several said other developer tools offer similar benefits.

"There's no doubt that webOS has its fans," said Stephen O'Grady, an open-source expert with the RedMonk analyst firm. "But at the end of the day, for most developers the attractiveness of the platform is a direct function of the size of that platform's audience, and for webOS, at this point, it's a rounding error."

Like Hilwa, however, O'Grady suggested there could be demand for using webOS in niche devices such as retail kiosks, printers or industrial equipment.

Other webOS enthusiasts have suggested that some phone or gadget-makers may ultimately turn to webOS as an alternative to paying royalties for Android, which has been hit with patent infringement claims from Microsoft, Oracle (ORCL) and others.

"An open-source webOS, backed by HP or Palm's patent portfolio, should be an attractive alternative to the existing, entrenched mobile platforms," suggested Rod Whitby, the Australian leader of a loose-knit group of "home brew" programmers called WebOS Internals.

Contact Brandon Bailey at 408-920-5022; follow him at Twitter.com/BrandonBailey

Mobile software Platforms

HP's webOS lagged far behind other smartphone operating systems in number of users, according to comScore's report on U.S. market share in the fourth quarter of 2011:

Google (Android): 47.3 percent.
Apple (IS):
29.6 percent.
RIM (Blackberry):
16 percent.
Microsoft (Windows Mobile/
Windows Phone):
4.7 percent.
Symbian (used by Nokia): 1.4 percent.
HP/Palm (webOS):
1 percent.

Source: comScore
Mobile's

Continued here:
After scrapping bigger plans, HP says webOS still has an open-source future

UCLA Discovery that Migrating Cells "Turn Right' has Implications for Engineering Tissues, Organs

Embargoed for Use Until
4 p.m. (EST), Feb. 17, 2012

Newswise — What if we could engineer a liver or kidney from a patient's own stem cells? How about helping regenerate tissue damaged by diseases such as osteoporosis and arthritis? A new UCLA study bring scientists a little closer to these possibilities by providing a better understanding how tissue is formed and organized in the body.

A UCLA research team discovered that migrating cells prefer to turn right when encountering changes in their environment. The researchers were then able to translate what was happening in the cells to recreate this left–right asymmetry on a tissue level. Such asymmetry is important in creating differences between the right and left sides of structures like the brain and the hand.

The research, a collaboration between the David Geffen School of Medicine at UCLA and the Center for Cell Control at UCLA's Henry Samueli School of Engineering and Applied Science, appears in the Feb. 17 issue of the journal Circulation Research.

"Our findings suggest a mechanism and design principle for the engineering of tissue," said senior author Dr. Linda L. Demer, a professor of medicine, physiology and bioengineering and executive vice chair of the department of medicine at the Geffen School of Medicine. "Tissue and organs are not simply collections of cells but require careful architecture and design to function normally. Our findings help explain how cells can distinguish and develop highly specific left–right asymmetry, which is an important foundation in tissue and organ creation."

Using microtechnology, the team engineered a culture surface in the lab with alternating strips of protein substrates that were cell-adhesive or cell-repellent, analogous to a floor with narrow horizontal stripes of alternating carpet and tile. Cells may encounter such surface changes when they travel through the body.
?
The researchers observed that as the migrating cells crossed the interface between "carpet" and "tile" sections, they exhibited a significant tendency to turn right by 20 degrees, and, like a marching band, lined up in long, parallel rows, producing diagonal stripes over the entire surface.

"We had been noticing how these vascular cells would spontaneously form structures in cultures and wanted to study the process," said first author Ting-Hsuan Chen, a graduate student researcher in the department of mechanical and aerospace engineering at UCLA Engineering. "We had no idea our substrates would trigger the left–right asymmetry that we observed in the cells. It was completely unexpected.

"We found that cells demonstrated the ability to distinguish right from left and to self-organize in response to mechanical changes in the surfaces that they encounter. This provides insight into how to communicate with cells in their language and how to begin to instruct them to produce tissue-like architecture."

According to the researchers, the cells can sense the substrates beneath them, and this influences the direction of their migration and what shapes they form in the body. Of most interest, the researchers said, was the fact that the cells responded to the horizontal stripes by reorganizing themselves into diagonal stripes.

The team hopes to harness this phenomenon to use substrate interfaces to communicate with cells and instruct them to produce desired tissue structures for replacement. By adjusting the substrates, the researchers say, they have the potential to guide what structures the cells and tissue form.

The next stage of the research will be to control and guide cells to self-organize into two-dimensional and, eventually, three-dimensional patterns chosen by the researchers.

According to the research team, this is one of the first studies to demonstrate that encountering a change in substrate can trigger a cell's preference for turning left or right. It is also one of the first studies showing that cells can integrate left–right asymmetry into a patterned structure of parallel diagonal stripes resembling tissue architecture.

"Applications for this research may help in future engineering of organs from a patient's own stem cells," Demer said. "This would be especially important given the limited supply of donor organs for transplant and problems with immune rejection."

The study was funded by the National Science Foundation and National Institutes of Health.

Additional authors included Jeffrey J. Hsu, Alan Garfinkel and Yin Tintut from the UCLA Department of Medicine; Yi Huang and Chih-Ming Ho from the UCLA Department of Mechanical and Aerospace Engineering; Xin Zhao, Chunyan Guo and Zongwei Li from the

Institute of Robotics and Automatic Information System at China's Nankai University; and Margaret Wong from the UCLA Department of Bioengineering.

For more news, visit the UCLA Newsroom and follow us on Twitter.

Comment/Share

View original post here:
UCLA Discovery that Migrating Cells "Turn Right' has Implications for Engineering Tissues, Organs

Bioengineering company bringing ideas to Huntington

HUNTINGTON -- Hongwei Yu, chief science officer and co-founder of Progenesis Technologies, is in the market for new business cards after the company hosted a grand opening in its new Huntington office and lab in the Red Cross Building .

As West Virginia's only locally owned and operated genetic engineering company, Progenesis recently changed its address from South Charleston to Huntington, a move that was celebrated during a grand opening at the new office Friday.

The company has long had ties to Huntington, as it is a spin-off of sorts from Marshall University, where Yu is a professor.

The company, which was founded in 2008, had been operating out of South Charleston until moving into the Red Cross Building and beginning renovations in January.

Most of the Progenesis work force lives in Huntington, so Friday's grand opening had been eagerly anticipated, Yu said.

"We are very excited to get to work so close to home," Yu said. "It will make a big difference between shuttling back and forth. We work with the Biotechnology Center at Marshall, so this will allow us to come in anytime we want to or need to and be able to do our work more efficiently."

Progenesis is a research and development company, which is focused on demonstrating the feasibility of manufacturing its genetically-engineered bacterial alginates on an industrial scale.

Bacterial alginates absorb water quickly, which makes them useful in everything from the agricultural and food industries to the cosmetic and drug markets.

In addition to the new office space, Progenesis' new digs include a bigger, brighter lab space for employees to do their work in, said Richard Niles, CEO of Progenesis.

"It really is going to be a wonderful place to work," Niles said. "We are on an upward curve of developing our product and the company, and these new facilities are part of the attraction of significant revenue that will allow us to add more employees, which is what we need to continue to produce and test the product of this company."

While the company is the only one of its kind in the state, Niles said he sees a bright future for biotechnology in Huntington.

"We are part of a new group of companies, which, locally, includes Vandalia, in biotechnology, which is a growing field. It's one that is going to diversify the economy in Huntington," Niles said. "Anyone who is curious about what we do is welcome to come and look at what it is we're doing. All it takes is giving us a call setting up a time to visit."

Follow this link:
Bioengineering company bringing ideas to Huntington

Microchip successfully delivers bone-loss drug: study

A microchip inserted under the skin has been shown for the first time to successfully deliver a bone-loss drug to a small sample of women, according to US-led research published Thursday.

The device may someday allow patients to avoid daily injections of medication and permit doctors to adjust their doses from afar, said the study which appears in the journal Science Translational Medicine.

"We hope this really is the dawn of a whole new way of thinking about delivering medications," said co-author Robert Langer, a professor of cancer research at the Massachusetts Institute of Technology.

Langer and colleagues presented their findings at the annual meeting of the American Association for the Advancement of Science in Vancouver, Canada. Langer addressed the conference by phone.

The device is about the size of a pacemaker, or a computer flash stick, and contains daily doses of medication inside small wells that open up either on a predetermined schedule, or when the chip is given a wireless signal to release the drugs.

Each well is covered by a nano-thin layer of gold which protects the drug and prevents it from being released.

The wireless signal causes the gold to dissolve and allows the drug to enter the bloodstream.

In this case, researchers tested the device on seven women aged 65-70 in Denmark who were prescribed the drug teriparatide for osteoporosis. The microchip was implanted just below their waistlines.

After tracking the women for 12 months, researchers found that the treatment improved bone formation and reduced the risk of bone fracture, and delivered the drug just as effectively as daily injections.

However, the same issues that raised concerns in animal studies were also observed in the women: the formation of fibrous collagen-based tissue around the microchip.

The presence of the tissue had raised concerns among researchers over its potential to interrupt drug delivery, though no such problems were observed in the one-year study, after which the women had the chips removed.

Lead author Robert Farra, president and chief operating officer at MicroCHIPS, which was founded by some of the researchers and licensed the microchip technology from MIT, said the device is best suited for potent drugs needed in small but regular doses.

"For the 200 million people worldwide with osteoporosis, and for patients with many other diseases, taking a daily injection is not an appealing way to take every day for a chronic disease that you may face for the rest of your life."

No adverse events were observed in the patients in the study, though one had a device implanted that malfunctioned and did not release the drugs. Farra told reporters that diagnostic changes have been made to prevent such problems in the future.

He added that the cost was likely to be $10,000-$12,000 per year, comparable to the current costs of administering the osteoporosis drug that the team tested.

Scientists plan to continue studies on the microchip delivery system in heart disease, multiple sclerosis, cancer and chronic pain. The device is likely about five years away from potential market approval, the authors said.

The technology was first envisioned about 15 years ago, and according to an accompanying editorial in the journal by John Watson, a professor of bioengineering at the University of California, many questions still remain.

Among them, how reliable and durable the chip may be over time, and how it may be adapted to other diseases -- a process he likened to a meandering path with many sharp turns.

"For Farra, Langer, and colleagues, the 'hairpin' road to the clinic might be long and winding, but a versatile implantable device that exploits the microchip approach for controlled drug delivery will be well worth the wait for patients with chronic diseases," Watson wrote.

Continued here:
Microchip successfully delivers bone-loss drug: study

Microchip delivers drug; can it replace shots?

CHICAGO (Reuters) - An implantable, wireless microchip delivered osteoporosis medicine to a small group of Danish women, raising hope for a new kind of drug delivery device that might allow patients to skip regular injections, U.S. researchers said on Thursday.

The device, now being developed by privately held Microchips Inc, has a wireless receiver that signals the microchip to release the drug.

"Until now, you never had any way you could do this," said Dr. Robert Langer of the Massachusetts Institutes of Technology, who helped to develop the technology and is a board member of Microchips Inc.

Langer said the device could be used for different types of injectable drugs where getting people to take their medications regularly is a problem.

That is often the case in patients with severe osteoporosis, who tend to skip doses of their medications because they cannot tell whether or not the injections are affecting the density of their bones.

That is something the microchip was designed to overcome, said Robert Farra of Massachusetts-based Microchips, which paid for the study. Farra, Langer and colleagues published a paper on the study in Science Translational Medicine.

Instead of constantly releasing small amounts of drug, like most drug-delivery systems, the microchip releases medication on command all at once, much like an injection would.

It can be activated by telephone or computer using a special radiofrequency reserved for medical use to safeguard against accidental release of the drug, Langer said.

GOLD NANOPARTICLES

The microchip itself is a thin wafer, about the size of a small coin, made with tiny wells that hold concentrated doses of medication. These doses are covered with a layer of gold nanoparticles, which dissolve when exposed to a certain radiofrequency. The wafer is implanted under the skin with a receiver device that is roughly the size of a heart pacemaker, Langer said.

In the system's first test in people, the team implanted the device in eight Danish women aged 65 to 70 with a severe form of osteoporosis which required injections of Eli Lilly & Co's hormone treatment teriparatide.

The researchers sent daily signals to the microchip device to release the drug for up to 20 doses. Then, they followed up with a period in which the women took hormone injections.

As seen in animal studies, a fibrous collagen-based membrane developed around the device, but the drug still performed just as well as daily injections in the women, improving bone formation and reducing the risk of fractures, the researchers said.

Still, there were some hitches.

John Watson, a professor of bioengineering at the University of California, San Diego, said in an editorial the device failed to work in one of the patients, and that data was not included in the analysis.

And the team had some manufacturing issues and was able to manufacture only one device with all 20 reservoirs filled with the study drug. Even so, all doses in the microchips were released in the patients, a sign that the device could work in people, Watson said.

"Several years are still needed to bring this technology to approval by the U.S. Food and Drug Administration and to the clinical promise reflected in this small study," Watson wrote.

The current device holds only 20 doses, but Langer said the group is working on adding more doses to the device.

The company hopes to have a version of the device on the market in five years. Langer said he sees potential for other uses, such as treating diabetes or delivering cancer drugs.

SOURCE: http://bit.ly/xUUOwu Science Translational Medicine, February 16, 2012.

Read the original here:
Microchip delivers drug; can it replace shots?

Lewis: Fully caffeinated professor dreams up business

If you haven't accomplished enough in your life, it may be because you're not getting enough caffeine.

David Edwards starts his days with a couple of shots of espresso, and by the afternoon he is more or less inhaling caffeine.

The result has been impressive for a Midwestern boy from Ann Arbor, Mich., who admits he used to drag along in school.

Now, at 50 years of age, Edwards has published papers, books and novels. He's earned a PhD in chemical engineering. He teaches bioengineering at Harvard University, but he lives in Paris, where he is married to a French woman and serves as director of Le Laboratoire, a contemporary art and design center. His life's work spans the arts and sciences, from the culinary to the pharmaceutical. And lately he's been spinning off his greatest ideas into venture-capital-financed companies.

One of these companies is peddling an alarming new product called Aeroshot.

It comes in what looks like a shotgun shell. You huff on it like a pipe for an instant blast of caffeine powder. It's now on sale for $2.99 in Boston and New York, and at http://www.aeroshots.com.

So far, sales have been brisk, Edwards says. His product targets the young and the experimental, from college kids to 30-somethings--you know, the same people you see downing shots of 5-Hour Energy or slamming cans of Red Bull, Rockstar and Reload.

U.S. Sen. Charles Schumer calls Aeroshot a "club drug" and a "party enhancer." Schumer has asked the Food and Drug Administration to have a look at it. A similar request the senator once made put a sudden end to the idea of loading malt liquor drinks with caffeine, such as Jooze and Four Loko. Thanks to Schumer, consumers now have to find a corner where there is both a bar and a Starbucks.

Schumer is afraid children may get their hands on this stuff.

"This was an easy shot for him," Edwards says. "We completely agree with the senator that encouraging caffeine use among kids is not healthy, and it's not what we want to do."

For all of Schumer's grandstanding, Aeroshot is but an incremental technological improvement that merely changes the delivery mechanism of a substance found in Coke and Pepsi.

Why do we have to drink caffeine? Why not huff it like glue? Snort it like cocaine? Smoke it crystal meth? Or shoot it up like speed? How else are we supposed to get our work done?

Edwards says it's not quite like that. With Aeroshot, no caffeine enters lungs because the grains are too large to go down the windpipes, he says. The act of breathing simply coats the mouth and tongue, where the caffeine powder is quickly absorbed.

Each tube comes with 100 milligrams, or about the same dose as a cup of coffee. Since it's typically consumed in multiple breaths, consumers can more easily control their intake.

"This helps you use caffeine more wisely," Edwards says. "You take what you need when you need it, and you can actually get more for less."

I can't be sure how much of this stuff Edwards has inhaled, but some of his ideas seem a little trippy. One of his works of fiction, for instance, explores the question of whether an artist would discover the meaning of intelligence if he became a stem cell and then divided into a neuron.

Edwards also has invented breathable chocolate. "It's chocolate stimulation without the calories of pure chocolate," he explains.

And Edwards is developing breathable medicines, breathable vitamins, breathable foods and even breathable cocktails. The breathable caffeine, he says, was just to target a market where he thought he could get instant traction. At least he got instant Congressional attention.

"Inevitably, there are those who are comfortable with this, and those who are not," Edwards says. "We think this is a billion-dollar business."

That's more than enough to keep him up at night.

"There's a long history of caffeine being a creative stimulant," he says.

"It's probably part of the reason why I only sleep five hours a night....I'm not a big sleeper."

Al Lewis: 212-416-2617 or al.lewis@dowjones.com; read his blog at tellittoal.com.

Read the rest here:
Lewis: Fully caffeinated professor dreams up business

Histogenics to Present at 7th Annual New York Stem Cell Summit

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated.

Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit http://www.histogenics.com.

See the article here:
Histogenics to Present at 7th Annual New York Stem Cell Summit

Titan Spine Acquires Additional Patent Protection for its Spinal Implant Surface Technologies

MEQUON, Wis.--(BUSINESS WIRE)--

Titan Spine, a medical device surface technology company focused on the development of innovative spinal interbody fusion implants, announced today that it has acquired two patents related to its current and future surface modification techniques. The first patent protects the company’s existing manufacturing process that has been shown to produce superior bone-forming activity when compared to standard PEEK and titanium implant materials during in-vitro cellular studies and has been commercially available in the United States since 2006. The second patent protects Titan Spine’s next-generation surface technology that further refines its nano features, which the company expects to produce an even more robust osteogenic response.

Barbara Boyan, Ph.D., Professor of Biomedical Engineering at the Institute for Bioengineering and Bioscience, Georgia Institute of Technology, is conducting in-vitro cellular studies on the company’s newer surface. She commented, “Nano technology is beginning to come to the forefront of the spinal industry. Even small modifications to the surface of a spinal implant at the micro and nano levels can have a profound effect on the biological response to the device, which, in turn, can influence the patient’s surgical outcome. Titan Spine has been pioneering this effort for many years and is continuing to evolve surface modification techniques to elicit increasingly beneficial results.”

“The acquisition of these two patents is important to the company on several fronts,” said Kevin Gemas, President of Titan Spine. “Not only does it significantly strengthen our Intellectual Property profile and protect our next-generation surface through 2023, but it also demonstrates our commitment to the growing belief in the spinal industry that interbody devices should do more than just act as a spacer in a marketplace where spine surgeons are increasingly being forced to change from their biologic material of choice. And lastly, but perhaps most important of all, these acquisitions create the potential for us to apply our scientific and manufacturing know-how to other medical device applications.”

About the Company – Titan Spine, LLC is a privately-owned medical implant surface technology company in Mequon, Wisconsin that is focused on the design and manufacturing of proprietary interbody fusion devices for the spine. The company is committed to advancing the science of surface engineering to enhance the treatment of various pathologies of the spine that require fusion. Visit http://www.titanspine.com to learn more and to view an animation that depicts the cellular response to the company’s surface technology.

Read the original post:
Titan Spine Acquires Additional Patent Protection for its Spinal Implant Surface Technologies

Speaker to discuss Honor Code at UPUA meeting

February 15, 2012

Associate Professor of Bioengineering and Surgery Keefe Manning is scheduled to address student leaders at tonight’s UPUA meeting.

Manning plans to give a special presentation regarding the Honor Code and Academic Integrity Task Force, Chairwoman of the Assembly Kelly Terefenko wrote in an email.

Terefenko (senior-international politics and national security) said the task force has been charged with formulating a university-wide honor code, and Manning will present an initial progress report at the general assembly meeting.

Manning is a co-chair on the task force alongside Associate Professor of Human Development and Family Studies Pamela Hufnagel. The task force was introduced on Nov. 1 in order to look into the possibility of creating an honor code at Penn State, Manning said.

The task force began by looking at various institutions across the country to see which had honor codes and which honor codes were successfully employed, Manning said. He added that the presentation to the University Park Undergraduate Association is the next step in the task force’s progress.

As of now, the task force is still gathering feedback from students and staff and plans on presenting their ideas to other student groups such as the Council of Commonwealth Student Governments.

Manning said that if an honor code is installed, it will not be looked at as a “code,” but more so a statement summarizing the ideals that Penn State, as a university, stands for.

“We’re looking at it as a statement of honor and integrity,” Manning said. “This is an all-encompassing umbrella — it is a central theme of Penn State principles.”

Apart from Manning’s presentation, one new piece of legislation will be introduced at the meeting.

The resolution, which Terefenko said she wrote personally, involves releasing funds for the 2012 student handbook, referred to as “The ‘S’ Book.” Terefenko said the project was already budgeted at the beginning of the semester, and this new legislation outlines specific details regarding the student handbooks.

Terefenko said the legislation stipulates that UPUA will print a total of 8,500 books — 7,500 to be distributed to all incoming freshman at the earliest FTCAP meeting on May 5, and 1,000 to be used for student activities and programs such as LinkUP and Winter Welcome.

UPUA spent about $14,000 on “S Books” for the 2011-2012 academic year.

The book includes a small campus map, screen shots of the eLion and Angel websites, interesting facts about Penn State and the lyrics to Penn State’s Alma Mater and fight songs.

Governmental Affairs Chair Adam Boyer said he thinks it’s a good idea that student handbooks will be distributed during the FTCAP day.

In 2010 and 2011, UPUA didn’t distribute all of the books to freshman as scheduled.

Boyer (senior-history and political science) added he thinks it’s too overwhelming for new students to receive the handbooks in their mailboxes at a time when they will be “flooded” with so much new information at the start of a semester.

Boyer said that the handbooks are not just meant for freshmen, but all incoming students to utilize.

Collegian staff writer Aria Moyer contributed to this report.

 

Read the original post:
Speaker to discuss Honor Code at UPUA meeting